Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot
Code deleted, see 80339, 80340, 80341

Official Description

Methsuximide

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 83858 refers to a laboratory test specifically designed to measure the levels of methsuximide in the blood. Methsuximide, which is marketed under the brand name Celontin, is classified as a succinimide anticonvulsant medication. It is primarily utilized in the management of absence seizure disorders, which are characterized by brief episodes of impaired consciousness. The measurement of methsuximide levels is crucial for monitoring therapeutic drug levels in patients undergoing treatment, ensuring that the medication is effective while minimizing the risk of toxicity. The test involves obtaining a blood sample through a procedure known as venipuncture, which is a separate reportable service. The analysis of the serum or plasma is conducted using quantitative gas chromatography, a precise method that allows for the accurate quantification of the drug concentration in the blood. This testing is essential for healthcare providers to make informed decisions regarding dosage adjustments and overall treatment efficacy for patients with seizure disorders.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The procedure associated with CPT® Code 83858 is indicated for the following conditions:

  • Monitoring Therapeutic Levels The test is performed to monitor the levels of methsuximide in patients who are being treated for absence seizure disorders, ensuring that the drug concentration remains within a therapeutic range.
  • Assessing Drug Efficacy It helps in assessing the efficacy of methsuximide therapy in controlling seizures, allowing healthcare providers to make necessary adjustments to the treatment plan.
  • Evaluating Potential Toxicity The test is also indicated for evaluating potential toxicity in patients who may be experiencing adverse effects from methsuximide, ensuring patient safety and effective management of side effects.

2. Procedure

The procedure for obtaining a methsuximide level involves several key steps that ensure accurate testing and patient safety:

  • Step 1: Patient Preparation Prior to the blood draw, the patient may be instructed to avoid certain medications or food that could interfere with the test results. It is essential to ensure that the patient is adequately informed about the procedure and any necessary preparations.
  • Step 2: Venipuncture A qualified healthcare professional performs venipuncture, which involves inserting a needle into a vein, typically in the arm, to collect a blood sample. This step is crucial as it must be done carefully to minimize discomfort and ensure a sufficient volume of blood is obtained for testing.
  • Step 3: Sample Handling After the blood sample is collected, it is properly labeled and handled according to laboratory protocols to prevent contamination. The sample is then processed to separate the serum or plasma, which is necessary for the subsequent analysis.
  • Step 4: Quantitative Gas Chromatography The serum or plasma is subjected to quantitative gas chromatography, a sophisticated analytical technique that allows for the precise measurement of methsuximide levels in the blood. This method is essential for obtaining accurate and reliable results.

3. Post-Procedure

After the procedure, the patient may experience minor discomfort at the venipuncture site, which typically resolves quickly. It is important for healthcare providers to monitor the patient for any immediate adverse reactions. The results of the methsuximide level test will be analyzed and reported back to the prescribing physician, who will use this information to make informed decisions regarding the patient's ongoing treatment plan. Patients may be advised to follow up with their healthcare provider to discuss the results and any necessary adjustments to their medication regimen.

Short Descr ASSAY OF METHSUXIMIDE
Medium Descr METHSUXIMIDE
Long Descr Methsuximide
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 9 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
APC Status Indicator Items and Services Packaged into APC Rates
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE Not applicable/unspecified.
CCS Clinical Classification 233 - Laboratory - Chemistry and Hematology
Date
Action
Notes
2015-01-01 Deleted Code deleted, see 80339, 80340, 80341
2011-01-01 Changed Guideline information changed.
Pre-1990 Added Code added.
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"